Filing Details
- Accession Number:
- 0001209191-19-025794
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-24 18:16:20
- Reporting Period:
- 2019-04-22
- Accepted Time:
- 2019-04-24 18:16:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1595893 | Turning Point Therapeutics Inc. | TPTX | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1055951 | Orbimed Advisors Llc | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 225 San Diego CA 92121 | Yes | No | No | No | |
| 1682115 | Orbimed Capital Gp Vi Llc | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 225 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-22 | 1,120,730 | $0.00 | 1,120,730 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-04-22 | 546,820 | $0.00 | 1,667,550 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2019-04-22 | 360,000 | $18.00 | 2,027,550 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series C Preferred Stock | Disposition | 2019-04-22 | 4,314,809 | $0.00 | 1,120,730 | $0.00 |
| Common Stock | Series D Preferred Stock | Disposition | 2019-04-22 | 2,105,259 | $0.00 | 546,820 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
- These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VII") is the sole general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
- This report on Form 4 is jointly filed by GP VI and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange At of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently Carl L. Gordon ("Gordon"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- The shares were purchased at the Issuer's initial public offering.
Billionaire Hedge Funds
